Eli Lilly has signed a deal worth $1.3 billion with privately held Superluminal Medicines to discover and develop ...

Eli Lilly (LLY) has signed a $1.3 billion deal with privately held biotechnology firm Superluminal Medicines that will see ...

(Reuters) -Superluminal Medicines said on Thursday it had signed a deal with U.S. drugmaker Eli Lilly worth up to $1.3 ...

Boston: Superluminal Medicines, a drug discovery company integrating AI/ML, protein dynamics, and structural biology to ...

Having backed Superluminal Medicines’ series A last year, Eli Lilly has now signed a $1.3 billion pact with the G ...

Superluminal partners with Eli Lilly to develop AI-driven small molecule therapies targeting GPCRs for obesity and ...

Eli Lilly and Co (NYSE: LLY) has entered into a $1.3 billion deal with Superluminal Medicines to develop small-molecule drugs ...

The Boston-based AI/ML startup focuses on endocrine and cardiometabolic diseases and will use that expertise to generate new ...

Eli Lilly (LLY) recently collaborated with Superluminal Medicines to advance therapeutics targeting cardiometabolic diseases, ...

Yahoo Finance anchor Julie Hyman tracks Thursday's top stocks and market movers in this Market Minute. C3.ai (AI) stock dips ...

Superluminal partners with Eli Lilly to advance AI-driven small molecule therapeutics for cardiometabolic diseases.

Lilly will receive exclusive rights to develop and commercialize drug candidates discovered using Superluminal's AI-driven ...